(NOVC.DE) Stock Fundamental Analysis
Europe - FRA:NOVC - DK0060534915 - Common Stock
86.34 EUR
-2.03 (-2.3%)
Taking everything into account, NOVC scores 7 out of 10 in our fundamental rating. NOVC was compared to 49 industry peers in the Pharmaceuticals industry. NOVC has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. NOVC is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes NOVC very considerable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year NOVC was profitable.
NOVC had a positive operating cash flow in the past year.
NOVC had positive earnings in each of the past 5 years.
NOVC had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 23.95%, NOVC belongs to the best of the industry, outperforming 95.56% of the companies in the same industry.
NOVC's Return On Equity of 74.32% is amongst the best of the industry. NOVC outperforms 95.56% of its industry peers.
The Return On Invested Capital of NOVC (55.96%) is better than 97.78% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for NOVC is significantly above the industry average of 15.25%.
The 3 year average ROIC (49.65%) for NOVC is below the current ROIC(55.96%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 23.95% | ||
| ROE | 74.32% | ||
| ROIC | 55.96% |
ROA(3y)25.55%
ROA(5y)28.51%
ROE(3y)66.85%
ROE(5y)68.54%
ROIC(3y)49.65%
ROIC(5y)55.99%
1.3 Margins
Looking at the Profit Margin, with a value of 33.40%, NOVC belongs to the top of the industry, outperforming 91.11% of the companies in the same industry.
NOVC's Profit Margin has declined in the last couple of years.
NOVC's Operating Margin of 42.80% is amongst the best of the industry. NOVC outperforms 95.56% of its industry peers.
NOVC's Operating Margin has been stable in the last couple of years.
NOVC's Gross Margin of 84.35% is amongst the best of the industry. NOVC outperforms 84.44% of its industry peers.
In the last couple of years the Gross Margin of NOVC has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.8% | ||
| PM (TTM) | 33.4% | ||
| GM | 84.35% |
OM growth 3Y-0.97%
OM growth 5Y-0.64%
PM growth 3Y-0.57%
PM growth 5Y-1.67%
GM growth 3Y-0.02%
GM growth 5Y-0.07%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), NOVC is creating value.
NOVC has less shares outstanding than it did 1 year ago.
NOVC has a better debt/assets ratio than last year.
2.2 Solvency
NOVC has an Altman-Z score of 11.18. This indicates that NOVC is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of NOVC (11.18) is better than 93.33% of its industry peers.
The Debt to FCF ratio of NOVC is 0.38, which is an excellent value as it means it would take NOVC, only 0.38 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.38, NOVC belongs to the top of the industry, outperforming 91.11% of the companies in the same industry.
A Debt/Equity ratio of 0.21 indicates that NOVC is not too dependend on debt financing.
NOVC has a Debt to Equity ratio of 0.21. This is comparable to the rest of the industry: NOVC outperforms 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 0.38 | ||
| Altman-Z | 11.18 |
ROIC/WACC7.69
WACC7.28%
2.3 Liquidity
NOVC has a Current Ratio of 0.88. This is a bad value and indicates that NOVC is not financially healthy enough and could expect problems in meeting its short term obligations.
NOVC's Current ratio of 0.88 is on the low side compared to the rest of the industry. NOVC is outperformed by 84.44% of its industry peers.
NOVC has a Quick Ratio of 0.88. This is a bad value and indicates that NOVC is not financially healthy enough and could expect problems in meeting its short term obligations.
NOVC has a Quick ratio of 0.70. This is amonst the worse of the industry: NOVC underperforms 82.22% of its industry peers.
The current and quick ratio evaluation for NOVC is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.7 |
3. Growth
3.1 Past
The earnings per share for NOVC have decreased strongly by -32.68% in the last year.
NOVC shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.48% yearly.
The Revenue has grown by 28.03% in the past year. This is a very strong growth!
Measured over the past years, NOVC shows a quite strong growth in Revenue. The Revenue has been growing by 9.64% on average per year.
EPS 1Y (TTM)-32.68%
EPS 3Y3.69%
EPS 5Y3.48%
EPS Q2Q%-26.37%
Revenue 1Y (TTM)28.03%
Revenue growth 3Y13.19%
Revenue growth 5Y9.64%
Sales Q2Q%31.59%
3.2 Future
NOVC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.79% yearly.
NOVC is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.65% yearly.
EPS Next Y96.77%
EPS Next 2Y52.67%
EPS Next 3Y40.31%
EPS Next 5Y25.79%
Revenue Next Year27.56%
Revenue Next 2Y22.92%
Revenue Next 3Y20.4%
Revenue Next 5Y13.65%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 43.17, the valuation of NOVC can be described as expensive.
Based on the Price/Earnings ratio, NOVC is valued a bit more expensive than the industry average as 64.44% of the companies are valued more cheaply.
When comparing the Price/Earnings ratio of NOVC to the average of the S&P500 Index (27.41), we can say NOVC is valued expensively.
The Price/Forward Earnings ratio is 15.13, which indicates a correct valuation of NOVC.
NOVC's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. NOVC is cheaper than 64.44% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.88. NOVC is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.17 | ||
| Fwd PE | 15.13 |
4.2 Price Multiples
NOVC's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. NOVC is more expensive than 64.44% of the companies in the same industry.
The rest of the industry has a similar Price/Free Cash Flow ratio as NOVC.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 42.68 | ||
| EV/EBITDA | 30.33 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of NOVC may justify a higher PE ratio.
NOVC's earnings are expected to grow with 40.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.45
PEG (5Y)12.41
EPS Next 2Y52.67%
EPS Next 3Y40.31%
5. Dividend
5.1 Amount
NOVC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap386.28B
Analysts70.63
Price Target169.94 (96.83%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP41.57%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.26%
Min EPS beat(2)-6.63%
Max EPS beat(2)2.11%
EPS beat(4)3
Avg EPS beat(4)-0.09%
Min EPS beat(4)-6.63%
Max EPS beat(4)2.85%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)99180.3%
Min Revenue beat(2)97265.9%
Max Revenue beat(2)101095%
Revenue beat(4)4
Avg Revenue beat(4)100079%
Min Revenue beat(4)97265.9%
Max Revenue beat(4)101151%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.68%
PT rev (3m)6.75%
EPS NQ rev (1m)-50.34%
EPS NQ rev (3m)-49.42%
EPS NY rev (1m)0.22%
EPS NY rev (3m)4.6%
Revenue NQ rev (1m)-99.9%
Revenue NQ rev (3m)-99.9%
Revenue NY rev (1m)0.24%
Revenue NY rev (3m)3.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.17 | ||
| Fwd PE | 15.13 | ||
| P/S | 14.31 | ||
| P/FCF | 42.68 | ||
| P/OCF | 32.1 | ||
| P/B | 31.84 | ||
| P/tB | 72.51 | ||
| EV/EBITDA | 30.33 |
EPS(TTM)2
EY2.32%
EPS(NY)5.71
Fwd EY6.61%
FCF(TTM)2.02
FCFY2.34%
OCF(TTM)2.69
OCFY3.12%
SpS6.03
BVpS2.71
TBVpS1.19
PEG (NY)0.45
PEG (5Y)12.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 23.95% | ||
| ROE | 74.32% | ||
| ROCE | 69.41% | ||
| ROIC | 55.96% | ||
| ROICexc | 79.18% | ||
| ROICexgc | 187.85% | ||
| OM | 42.8% | ||
| PM (TTM) | 33.4% | ||
| GM | 84.35% | ||
| FCFM | 33.53% |
ROA(3y)25.55%
ROA(5y)28.51%
ROE(3y)66.85%
ROE(5y)68.54%
ROIC(3y)49.65%
ROIC(5y)55.99%
ROICexc(3y)59.43%
ROICexc(5y)70.56%
ROICexgc(3y)107.14%
ROICexgc(5y)103.87%
ROCE(3y)66.16%
ROCE(5y)72.5%
ROICexcg growth 3Y12.28%
ROICexcg growth 5Y2.92%
ROICexc growth 3Y-8.96%
ROICexc growth 5Y-9.74%
OM growth 3Y-0.97%
OM growth 5Y-0.64%
PM growth 3Y-0.57%
PM growth 5Y-1.67%
GM growth 3Y-0.02%
GM growth 5Y-0.07%
F-Score7
Asset Turnover0.72
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 0.38 | ||
| Debt/EBITDA | 0.21 | ||
| Cap/Depr | 278.9% | ||
| Cap/Sales | 11.04% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 100.38% | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.7 | ||
| Altman-Z | 11.18 |
F-Score7
WACC7.28%
ROIC/WACC7.69
Cap/Depr(3y)235.6%
Cap/Depr(5y)244.27%
Cap/Sales(3y)10.33%
Cap/Sales(5y)10.26%
Profit Quality(3y)95.36%
Profit Quality(5y)92.36%
High Growth Momentum
Growth
EPS 1Y (TTM)-32.68%
EPS 3Y3.69%
EPS 5Y3.48%
EPS Q2Q%-26.37%
EPS Next Y96.77%
EPS Next 2Y52.67%
EPS Next 3Y40.31%
EPS Next 5Y25.79%
Revenue 1Y (TTM)28.03%
Revenue growth 3Y13.19%
Revenue growth 5Y9.64%
Sales Q2Q%31.59%
Revenue Next Year27.56%
Revenue Next 2Y22.92%
Revenue Next 3Y20.4%
Revenue Next 5Y13.65%
EBIT growth 1Y29.73%
EBIT growth 3Y12.1%
EBIT growth 5Y8.94%
EBIT Next Year38.11%
EBIT Next 3Y23.19%
EBIT Next 5Y17.5%
FCF growth 1Y112.16%
FCF growth 3Y21.73%
FCF growth 5Y14.55%
OCF growth 1Y65.59%
OCF growth 3Y19.03%
OCF growth 5Y13.89%